Article: PPD Awarded U.S. Food and Drug Administration Contract to Evaluate FDA's Spontaneous Adverse Event Surveillance System.

Providing drug safety and pharmacoepidemiology expertise to assist agency in fulfilling PDUFA IV commitment

WILMINGTON, N.C. -- PPD, Inc. (Nasdaq: PPDI) today announced it has been awarded a contract by the U.S. Food and Drug Administration (FDA) to evaluate the agency's Center for Drug Evaluation and Research (CDER) post-market spontaneous adverse event surveillance system. The company will conduct a thorough evaluation of the value of the spontaneous adverse event reports to support safety-related regulatory actions and report its findings to the FDA and the public.

The award of $2.7 million for year one, is part of a two-year project of FDA's ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!